GSK (NYSE:GSK) Updates FY 2025 Earnings Guidance

GSK (NYSE:GSK - Get Free Report) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 4.250-4.590 for the period, compared to the consensus earnings per share estimate of 4.360. The company issued revenue guidance of $40.7 billion-$42.7 billion, compared to the consensus revenue estimate of $32.6 billion.

GSK Price Performance

Shares of GSK stock traded up $0.29 during trading on Friday, hitting $39.04. The company had a trading volume of 4,287,271 shares, compared to its average volume of 4,741,494. GSK has a 52 week low of $31.72 and a 52 week high of $45.93. The stock has a market capitalization of $80.55 billion, a price-to-earnings ratio of 24.55, a price-to-earnings-growth ratio of 1.12 and a beta of 0.51. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. The stock's 50-day moving average is $37.68 and its two-hundred day moving average is $36.04.

GSK (NYSE:GSK - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share for the quarter, beating the consensus estimate of $1.08 by $0.05. GSK had a net margin of 8.13% and a return on equity of 48.59%. The firm had revenue of $10.06 billion for the quarter, compared to analysts' expectations of $7.52 billion. During the same quarter last year, the company posted $0.43 EPS. The business's quarterly revenue was up 2.1% on a year-over-year basis. As a group, analysts predict that GSK will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 10th. Stockholders of record on Friday, May 16th will be issued a $0.4216 dividend. This is a boost from GSK's previous quarterly dividend of $0.39. This represents a $1.69 dividend on an annualized basis and a dividend yield of 4.32%. The ex-dividend date is Friday, May 16th. GSK's dividend payout ratio is presently 86.60%.

Analysts Set New Price Targets

GSK has been the subject of a number of recent research reports. Hsbc Global Res upgraded GSK to a "strong sell" rating in a research report on Monday, April 28th. BNP Paribas initiated coverage on shares of GSK in a research note on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 price objective for the company. Morgan Stanley started coverage on shares of GSK in a research report on Wednesday, February 12th. They issued an "equal weight" rating on the stock. Finally, StockNews.com upgraded shares of GSK from a "buy" rating to a "strong-buy" rating in a research report on Thursday, April 24th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $40.58.

Institutional Trading of GSK

An institutional investor recently bought a new position in GSK stock. Brighton Jones LLC acquired a new position in GSK plc (NYSE:GSK - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 15,604 shares of the pharmaceutical company's stock, valued at approximately $528,000. 15.74% of the stock is currently owned by institutional investors and hedge funds.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.